13F Holdings
中文EN

COR Cencora, Inc.

Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1140859 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.1%
TTM net income YoY38.3%
TTM EPS YoY38.3%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR15.8%

Margins

Gross margin4.0%
Operating margin0.9%
Net margin0.8%
FCF margin1.2%
EBITDA margin1.2%

Returns

ROE104.3%
ROA3.3%
ROIC (approx.)22.3%
Asset turnover4.22x

Leverage & solvency

Liabilities / assets96.1%
Debt / equity3.84x
Current ratio0.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.84x
Accruals ratio-2.8%
Payout ratio17.8%
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$321.33B$293.96B$262.17B$238.59B$213.99B
Cost of revenue$309.85B$284.05B$253.21B$230.29B$207.05B
Gross profit$11.48B$9.91B$8.96B$8.30B$6.94B
SG&A expense$6.49B$5.66B$5.31B$4.85B$3.59B
Operating income$2.63B$2.18B$2.34B$2.37B$2.35B
Pretax income$2.26B$2.00B$2.16B$2.18B$2.22B
Income tax$690.52M$484.70M$428.26M$516.52M$677.25M
Net income$1.55B$1.51B$1.75B$1.70B$1.54B
EBITDA$3.68B$3.27B$3.30B$3.06B$2.86B
EPS (basic)8.027.608.628.157.48
EPS (diluted)7.967.538.538.047.39
Dividends declared per share2.202.041.941.841.76
Weighted avg. shares (diluted)195.21M200.28M204.59M211.21M208.47M
Balance sheet
Cash & equivalents$4.36B$3.13B$2.59B$3.39B$2.55B
Receivables$25.23B$23.87B$20.91B$18.45B$18.17B
Inventory$20.49B$19.00B$17.45B$15.56B$15.37B
Current assets$52.24B$47.72B$42.80B$39.59B$38.80B
PP&E, net$2.54B$2.18B$2.14B$2.14B$2.16B
Goodwill$13.68B$9.32B$9.57B$8.50B$9.03B
Intangibles$3.77B$4.00B$4.43B$4.33B$5.26B
Total assets$76.59B$67.10B$62.56B$56.56B$57.34B
Current liabilities$57.82B$54.28B$48.83B$43.48B$41.36B
Short-term debt$117.78M$576.33M$641.34M$1.07B$300.21M
Long-term debt$7.54B$3.81B$4.15B$4.63B$6.38B
Total debt$7.66B$4.39B$4.79B$5.70B$6.68B
Total liabilities$74.84B$66.31B$61.89B$56.49B$56.75B
Shareholders' equity$1.51B$645.94M$522.00M-$211.56M$223.35M
Net debt$3.30B$1.26B$2.20B$2.31B$4.14B
Shares outstanding193.94M194.94M200.81M206.20M208.09M
Cash flow statement
Operating cash flow$3.88B$3.48B$3.91B$2.70B$2.67B
Capital expenditure$667.98M$487.17M$458.36M$496.32M$438.22M
Free cash flow$3.21B$3.00B$3.45B$2.21B$2.23B
Investing cash flow-$4.98B-$618.10M-$2.60B-$368.44M-$6.14B
Financing cash flow$2.25B-$2.33B-$2.22B-$1.75B$1.95B
Depreciation & amortization$1.05B$1.09B$963.90M$693.89M$505.17M
Stock-based compensation$147.96M$148.00M$124.62M$93.40M$99.59M
Dividends paid$437.08M$416.17M$398.75M$391.69M$366.65M
Share buybacks$435.47M$1.49B$1.18B$483.70M$82.15M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.